Skip to main content

Shengyun Fang, PhD

Academic Title:

Professor

Primary Appointment:

Pharmacology & Physiology

Secondary Appointment(s):

BioChemistry&Molecular Biology

Location:

111 S Penn St

Phone (Primary):

(410) 706-2220

Fax:

(410) 706-8184

Education and Training

MBBS, Clinical Medicine, Anhui Medical University, Anhui, China
Postdoctoral Associate, Physiology, University of Iowa, Iowa City, IA
PhD, Anatomy and Cell Biology, University of Iowa, Iowa City, IA
Postdoctoral Fellow, National Cancer Institute, Bethesda, MD

Biosketch

Dr. Fang is an accomplished expert in the field of the ubiquitin-proteasome system and the ER-associated degradation (ERAD) pathway. He is also deeply interested in understanding how ERAD dysfunction and the unfolded protein response (UPR) contribute to disease pathogenesis.

In recent years, Dr. Fang has re-focused his research on drug discovery through targeting the regulation of ER proteostasis, in collaboration with scientists at the National Center for Advancing Translational Sciences (NCATS). Currently, his lab is working on several small molecules, for examples, the first small molecule UBA1 activity enhancer and the first small molecule RNF5 inhibitor and degrader, that show great potential to be developed into first-in-class drugs. These drugs could help treat a wide range of disorders, including VEXAS syndrome, spinal muscular atrophy, α-1-antitrypsin deficiency-associated liver disease, obesity, obesity-related cancer, as well as aging and age-related diseases.

Research/Clinical Keywords

Proteostasis, UBA1 activity enhancers, RNF5 inhibitor and degrader, drug discovery, ubiquitination, ERAD, unfolded protein response, ER-phagy, VEXAS syndrome, spinal muscular atrophy, α-1-antitrypsin deficiency-associated liver disease, obesity-related cancer, aging, and age-related diseases.

Highlighted Publications

Ruan J, Liang D, Yan W, Zhong Y, Talley DC, Rai G, Tao D, LeClair CA, Simeonov A, Zhang Y, Chen F, Quinney NL, Boyles SE, Cholon DM, Gentzsch M, Henderson MJ, Xue F, Fang S.  A small-molecule inhibitor and degrader of the RNF5 ubiquitin ligase.  Mol Biol Cell. 2022 Nov 1;33(13):ar120.  PMCID: PMC9634977

Zhong Y, Yan W, Ruan J, Fang M, Yu C, Du S, Rai G, Tao D, Henderson MJ, Fang S.  XBP1 variant 1 promotes mitosis of cancer cells involving upregulation of the polyglutamylase TTLL6.  Hum Mol Genet. 2022 Aug 17;31(15):2639-2654.  PMCID: PMC9396943

Yan W, Zhong Y, Hu X, Xu T, Zhang Y, Kales S, Qu Y, Talley D, Baljinnyam B, LeCalir C, Simeonov A, Polster B, Huang R, Ye Y, Rai G, Henderson M, Tao D, Fang S.    Auranofin targets UBA1 and enhances UBA1 activity by facilitating ubiquitin trans-thioesterification to E2 ubiquitin-conjugating enzymes.  Nat Commun 2023 Aug 9;14(1):4798.  doi: 10.1038/s41467-023-40537-x.  PMCID: PMC10412574

Zhong Y, Wang J, Henderson MJ, Yang P, Hagen BM, Siddique T, Vogel BE, Deng HX, Fang S. Nuclear export of misfolded SOD1 mediated by a normally buried NES-like sequence reduces proteotoxicity in the nucleus. eLife. 2017 May 2;6. pii: e23759.  PMCID: PMC5449186

Liu Y, Gu Y, Chen Y, Wang X, Zhou G, Li J, Wang M*, Fang S*, Yang Y*. Translocational attenuation mediated by thePERK-SRP14 axis is a protective mechanism of unfolded protein response.Cell Rep. 2024 Jun 27;43(7):114402. doi: 10.1016/j.celrep.2024.114402. Online ahead of print.PMID:38943644

Additional Publication Citations

Grants and Contracts

×